Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 153 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Spinal Muscular Atrophy (SMA) Clear all

Conditions: Spinal Muscular Atrophy, Neuromuscular Diseases, SMA
Interventions: taldefgrobep alfa, Placebo; Drug
Lead sponsor: Biohaven Pharmaceuticals, Inc.; Industry
Eligibility: 4 Years to 21 Years
Enrollment: 269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 30
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 27 more

Conditions: Prostate Cancer, Prostatic Neoplasms
Interventions: Panobinostat, Bicalutamide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older · Male only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 4
States / cities: New Brunswick, New Jersey • Lake Success, New York • New York, New York + 1 more

Conditions: Muscular Atrophy, Spinal
Interventions: Risdiplam; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Miami, Florida • Orlando, Florida • San Antonio, Texas

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: Carelon Research; Other
Eligibility: 2 Years to 12 Years
Enrollment: 130 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Birmingham, Alabama • Stanford, California • Aurora, Colorado + 13 more

Conditions: Amyotrophic Lateral Sclerosis, Progressive Muscular Atrophy, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: Not listed
Enrollment: 25 participants
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Spinal Muscular Atrophy
Interventions: Risdiplam; Drug
Lead sponsor: Bakri Elsheikh; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: AC176; Drug
Lead sponsor: Accutar Biotechnology Inc; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 5
States / cities: Denver, Colorado • Sarasota, Florida • Detroit, Michigan + 2 more

Conditions: Spinal Muscular Atrophy
Interventions: Observational; Other
Lead sponsor: Columbia University; Other
Eligibility: 8 Years to 55 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Muscular Atrophy, Spinal
Interventions: Progressive strength training; Other
Lead sponsor: University of Utah; Other
Eligibility: 5 Years to 21 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy (DMD)
Interventions: Not listed
Lead sponsor: Columbia University; Other
Eligibility: 5 Years and older
Enrollment: 106 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Palo Alto, California • Boston, Massachusetts • New York, New York

Conditions: Spinal Muscular Atrophy Type 3, Duchenne Muscular Dystrophy
Interventions: Observational; Other
Lead sponsor: Columbia University; Other
Eligibility: 5 Years and older
Enrollment: 39 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Breast Cancer
Interventions: Enobosarm, Exemestane; Drug
Lead sponsor: Veru Inc.; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 34
States / cities: Chandler, Arizona • Gilbert, Arizona • Glendale, California + 29 more

Conditions: Spinal Muscular Atrophy (SMA)
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: Up to 6 Months
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 15
States / cities: Davis, California • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Spinal and Bulbar Muscular Atrophy, Kennedys Disease, Motor Neuron Disease
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years · Male only
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Spinal Muscular Atrophy
Interventions: OAV101, Sham control; Genetic · Procedure
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 6
States / cities: Farmington, Connecticut • Chicago, Illinois • Strasburg, Pennsylvania + 2 more

Conditions: Muscular Atrophy, Spinal
Interventions: Nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 7 Days and older
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Chicago, Illinois + 4 more

Conditions: Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy Type 2, Spinal Muscular Atrophy Type 3, Neuromuscular Manifestations, Anti-myostatin
Interventions: Apitegromab, Nusinersen, Risdiplam; Drug
Lead sponsor: Scholar Rock, Inc.; Industry
Eligibility: Up to 2 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 12
States / cities: Phoenix, Arizona • Orange, California • Palo Alto, California + 9 more

Conditions: Spinal Muscular Atrophy
Interventions: nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: Not listed
Enrollment: 292 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 18
States / cities: Los Angeles, California • Palo Alto, California • Aurora, Colorado + 15 more

Conditions: Motor Neuron Disease
Interventions: FLX-787-ODT (orally disintegrating tablet), Placebo ODT; Drug
Lead sponsor: Flex Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 35
States / cities: Scottsdale, Arizona • Sacramento, California • San Francisco, California + 29 more

Conditions: Muscular Atrophy, Spinal
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: Not listed
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Kalamazoo, Michigan • Salt Lake City, Utah

Conditions: Muscular Atrophy, Spinal
Interventions: Salanersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: 0 Days to 42 Days
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 3
States / cities: Chicago, Illinois • Flower Mound, Texas • Norfolk, Virginia

Conditions: Spinal Muscular Atrophy
Interventions: nusinersen; Drug
Lead sponsor: Biogen; Industry
Eligibility: Not listed
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Boston, Massachusetts • New York, New York • Dallas, Texas + 1 more

Conditions: Spinal Muscular Atrophy
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 5 Years to 20 Years
Enrollment: 24 participants
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia, Primary Lateral Sclerosis, Hereditary Spastic Paraplegia, Progressive Muscular Atrophy, Multisystem Proteinopathy
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 708 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2031
U.S. locations: 13
States / cities: Palo Alto, California • San Diego, California • San Francisco, California + 10 more

Search by objective public record fields.

A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics and Safety and Tolerability of a Single Oral Dose of Risdiplam Compared to Matched Healthy Participants With Normal Hepatic Function

A Pilot Study of Biomarkers for Spinal Muscular Atrophy

Study of ALS Reversals 4: LifeTime Exposures

Investigating NMJ Defects in SMA Following Central and Peripheral SMN Restoration

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Mechanisms and Treatment of Exercise Intolerance and Persistent Fatigue in Spinal Muscular Atrophy

Progressive Strength Training in Spinal Muscular Atrophy

Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders

Wearable Technology to Assess Gait Function in SMA and DMD

Efficacy Evaluation of Enobosarm Monotherapy in Treatment of AR+/ER+/HER2- Metastatic Breast Cancer

Spinal Muscular Atrophy (SMA) Biomarkers Study in the Immediate Postnatal Period of Development

Clinical, Molecular and Imaging Biomarkers in Spinal and Bulbar Muscular Atrophy (SBMA)

Efficacy and Safety of Intrathecal OAV101 (AVXS-101) in Pediatric Patients With Type 2 Spinal Muscular Atrophy (SMA)

Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy

A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy

A Study for Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in Nusinersen (ISIS 396443) Investigational Studies

A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

A Study to Collect Blood Samples From Patients With Spinal Muscular Atrophy for Biomarker Analysis

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

An Open-label Safety and Tolerability Study of Nusinersen (ISIS 396443) in Participants With Spinal Muscular Atrophy (SMA) Who Previously Participated in ISIS 396443-CS2 (NCT01703988) or ISIS 396443-CS10 (NCT01780246)

Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

Phenotype, Genotype & Biomarkers in ALS and Related Disorders